Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
Total Valuation
VistaGen Therapeutics has a market cap or net worth of $95.11M. The enterprise value is $3.04M.
Market Cap$95.11M
Enterprise Value$3.04M
Share Statistics
VistaGen Therapeutics has 30,680,471 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding30,680,471
Owned by Insiders1.77%
Owned by Institutions37.25%
Financial Efficiency
VistaGen Therapeutics’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -77.44%.
Return on Equity (ROE)-0.73
Return on Assets (ROA)-0.61
Return on Invested Capital (ROIC)-77.44%
Return on Capital Employed (ROCE)-0.78
Revenue Per Employee10.13K
Profits Per Employee-1.07M
Employee Count48
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VistaGen Therapeutics is ―. VistaGen Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.09
Price to FCF―
Price to Operating Cash Flow-1.87
PEG Ratio―
Income Statement
In the last 12 months, VistaGen Therapeutics had revenue of 486.00K and earned -51.42M in profits. Earnings per share was -1.67.
Revenue486.00K
Gross Profit486.00K
Operating Income-55.97M
Pretax Income-51.41M
Net Income-51.42M
EBITDA-55.34M
Earnings Per Share (EPS)-1.67
Cash Flow
In the last 12 months, operating cash flow was -50.07M and capital expenditures -46.00K, giving a free cash flow of -50.12M billion.
Operating Cash Flow-50.07M
Free Cash Flow-50.12M
Free Cash Flow per Share-1.63
Dividends & Yields
VistaGen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change-8.24%
50-Day Moving Average2.66
200-Day Moving Average2.61
Relative Strength Index (RSI)59.84
Average Volume (3m)583.93K
Important Dates
VistaGen Therapeutics upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
VistaGen Therapeutics as a current ratio of 6.51, with Debt / Equity ratio of 4.15%
Current Ratio6.51
Quick Ratio6.51
Debt to Market Cap0.00
Net Debt to EBITDA1.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VistaGen Therapeutics has paid 7.00K in taxes.
Income Tax7.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VistaGen Therapeutics EV to EBITDA ratio is -0.20, with an EV/FCF ratio of -0.26.
EV to Sales22.96
EV to EBITDA-0.20
EV to Free Cash Flow-0.26
EV to Operating Cash Flow-0.27
Balance Sheet
VistaGen Therapeutics has $63.18M in cash and marketable securities with $2.36M in debt, giving a net cash position of -$60.82M billion.
Cash & Marketable Securities$63.18M
Total Debt$2.36M
Net Cash-$60.82M
Net Cash Per Share-$1.98
Tangible Book Value Per Share$2.29
Margins
Gross margin is 73.84%, with operating margin of -11517.08%, and net profit margin of -10579.84%.
Gross Margin73.84%
Operating Margin-11517.08%
Pretax Margin-10578.40%
Net Profit Margin-10579.84%
EBITDA Margin-11386.42%
EBIT Margin-11517.08%
Analyst Forecast
The average price target for VistaGen Therapeutics is $9.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.17
Price Target Upside183.90% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-33.00%
EPS Growth Forecast54.91%